A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906)
Authors
Ka‐Won Kang (ORCID: https://orcid.org/0000-0003-1462-0502)
Kwai Han Yoo (ORCID: https://orcid.org/0000-0002-3049-9055)
Jun Ho Yi (ORCID: https://orcid.org/0000-0003-1499-7131)
A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906)
Ka‐Won Kang, Kwai Han Yoo, Jun Ho Yi, Sung‐Hoon Jung et al.
Journal
Cancer Research and Treatment
Topics
Multiple Myeloma Research and Treatments
article
A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906)
Ka‐Won Kang, Kwai Han Yoo, Jun Ho Yi, Sung‐Hoon Jung, Duck Cho, Sang Eun Yoon, Kihyun Kım, Jae Hoon Lee, Hyo Jung Kim, Joon Seong Park, Min Kyoung Kim, Chang‐Ki Min, Je‐Jung Lee, Sung-Hyun Kim
article en
Abstract
No abstract available for this paper.
Publication Tag
Cancer Research and Treatment
Institutions
Korea University (KR), Samsung Medical Center (KR), Gachon University Gil Medical Center (KR), Chonnam National University Hwasun Hospital (KR), Chung-Ang University Hospital (KR), Hallym University Sacred Heart Hospital (KR), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Yeungnam University College, Dong-A University (KR), Yeungnam University (KR), Ajou University (KR), Sungkyunkwan University (KR), Catholic University of Korea (KR)